Marrow transplantation for stable-phase chronic granulocytic leukemia

J. O. Armitage, L. W. Klassen, S. R. Patil, J. W. Kugler, R. D. Gingrich, G. B. Ahmann, M. A. Fyfe, H. H. Tewfik

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Ten patients with chronic granulocytic leukemia in the stable phase underwent marrow transplantation from HLA-identical siblings (nine cases) or an identical twin (one case) following preparation with cytarabine, cyclophosphamide, and total body irradiation. Marrow cytogenetics on all patients prior to transplantation revealed the Philadelphia chromosome without other evidence of aneuploidy. The immediate posttransplant course was in most cases relatively uncomplicated with only two serious infections and one death. All patients recovered with cytogenetically normal marrow and leukemia has recurred only in the syngeneic transplant recipient. At present, nine patients are surviving from 358 to 961 days (median 597 days) after bone marrow transplantation. Bone marrow transplantation is capable of eliminating the abnormal clone of myeloid cells in patients with stable-phase chronic granulocytic leukemia and can be performed relatively safely in this 'healthy' group of patients.

Original languageEnglish (US)
Pages (from-to)717-719
Number of pages3
JournalExperimental Hematology
Issue number9
StatePublished - 1984

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research


Dive into the research topics of 'Marrow transplantation for stable-phase chronic granulocytic leukemia'. Together they form a unique fingerprint.

Cite this